Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 studyQing Zhou, Yi‐Long Wu, Chong‐Rui Xu et al.|Cancer Cell|2021Cited by 232
Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at ResistanceZhen Wang, Yi‐Long Wu, Jin‐Ji Yang et al.|Journal of Thoracic Oncology|2017Cited by 220
Detection of Driver and Resistance Mutations in Leptomeningeal Metastases of NSCLC by Next-Generation Sequencing of Cerebrospinal Fluid Circulating Tumor CellsBen‐Yuan Jiang, Yi‐Long Wu, Yang-Si Li et al.|Clinical Cancer Research|2017Cited by 136
The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort studyXiao‐Feng Le, Ke Pan, Fangdi Sun et al.|Annals of Oncology|2025Cited by 9
Integrated histological and molecular analyses of rebiopsy samples at osimertinib progression improve post-progression survivals: A single-center retrospective studyJiangtao Cheng, Jin‐Ji Yang, Yihui Yao et al.|Lung Cancer|2020Cited by 9